Thus, an increase in fasting glucagon levels would be beneficial for both T1D patients and insulin dependent T2D patients, as both patient groups demonstrate a loss of glucagon secretion in response to hypoglycaemia. The gene discussed is GCG; the disease is type 1 diabetes mellitus.